Healthier LivesTM Promise of Delivering the...2019/08/08 · global market 6% CAGR over the next 5 years. $5B Sildenaﬁl preferred ED drug (>55% all sales) B2B, B2C and private clinics

Delivering the Promise of Healthier LivesTM

AUGUST 2019

OTCQB: CURROTCQB: CURR

®

Our mission is to improve lives by redefining how medications are delivered and experienced.

© 2

01

9 C

UR

E P

harm

aceutical

ForwardLookingStatements

To the extent any statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. When used in this presentation the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward looking statements.

Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Although the company believes that the expectations reflected in the forward looking statements are reasonable, the company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

© 2

01

9 C

UR

E P

harm

aceutical

The Challenge

In order for drugs to work, three factors must be carefully balanced:

Patients must take their drugs as prescribed.

ADHERENCE

SAFETY

EFFICACY

Too much drug in the body can cause serious side effects.

Enough drug must get into the body to be effective.

© 2

01

9 C

UR

E P

harm

aceutical

The Problem:Oral drug delivery is inefficient

© 2

01

9 C

UR

E P

harm

aceutical

With drug loss at each step, higher doses of oral drugs are often needed to achieve the therapeutic benefit.

This especially impacts poorly soluble drugs that are otherwise permeable to cells.

30% of drugs on the market and 70% or drugs in the pipeline fall into this category.*

*Biopharmaceutical Classification System Group 2

The Problem:Oral drug development is a balancing act

TOXICITY

EFFICACY

DOSAGE

© 2

01

9 C

UR

E P

harm

aceutical

The Problem:Oral drug administration is challenging

Patients suffer when drugs work too slowly or lack sufficient efficacy.

Lack of efficacy combined with side effects often deter patients from taking their medication as prescribed.

1 HealthPrize and Capgemini2 The Annals of Pharmacotherapy

Annual global revenues lost in pharma from medication non-adherence.1

$630B

Cost of non-optimized medication therapy in 2016

(16% of total US healthcare expenditures).2

$530B

© 2

01

9 C

UR

E P

harm

aceutical

The Solution:CUREform™

CUREform™

The RightFormulation

The Right Dosage Form

improves a drug’s solubility and bioavailability

changes its route of administration and

metabolism

CUREfilm®

CUREpods™

CUREdots™

The right formulation

AND

the right dosage form.

a proprietary oral formulation and delivery platform

© 2

01

9 C

UR

E P

harm

aceutical

CUREPharmaceutical

We are a drug delivery and development company with a proprietary oral formulation and delivery platform: CUREform™

We match or improve

pharmacokinetics of small

molecules for easier, safer

and more effective

administration.

We partner with innovative

companies to improve

investigational and marketed

drugs and dietary

supplements.

What we do How we do it

© 2

01

9 C

UR

E P

harm

aceutical

CUREdots™CUREfilm® CUREpods™

CUREform™Our oral formulation and delivery platform

© 2

01

9 C

UR

E P

harm

aceutical

CUREform™The Right Formulation

Encapsulation can:

● Protect molecules from degradation during the manufacturing process and throughout shelf life

● Protect molecules from degradation in the body (e.g. stomach acids)

● Increase palatability through improved taste masking

● Increase a drug’s bioavailability and optimize its release kinetics through:○ Increased solubility in water and therefore bodily fluids○ Enhanced permeability and retention in target tissue

We are developing several novel methods for encapsulating active ingredients for improved oral drug delivery.

At right: Microscopic view of micro-encapsulated Beta-Caryophyllene

© 2

01

9 C

UR

E P

harm

aceutical

CUREfilm®The Right Dosage Form

Per oral delivery On the tongue, swallowed and released in the stomach or intestines

Sublingual deliveryUnder the tongue and released into the bloodstream

Buccal delivery Between cheek and gum and released into the bloodstream

Proprietary oral dissolving film technology offers multiple delivery routes for optimal drug efficacy, safety and the patient experience.

© 2

01

9 C

UR

E P

harm

aceutical

CUREfilm®The Right Dosage Form

➽ Precision dosing

➽ Multiple and high-dose actives

➽ No need for water, swallowing or chewing

➽ Sublingual and buccal delivery for direct absorption into the bloodstream

This avoids:

● Drug exposure to stomach acids and tissue irritation

● Inefficient absorption through the intestines

● liver metabolism and potential injury

KEY BENEFITS

© 2019 CURE Pharmaceutical

CUREdotsTM


➽ Punch-hole size CUREfilm®

➽ Delivers actives to smaller animals

➽ Use for repetitive pharmacological and toxicological testing performed on animals

➽ Safe, convenient and humane alternative to oral gavage

KEY BENEFITS

© 2

01

9 C

UR

E P

harm

aceutical

CUREpodsTM

The Right Dosage FormProprietary pod technology encapsulates core ingredients in various ways, turning liquids and other ingredients into free powders that are simple to process, easy to dose and cost-effective to use.

CROSS-LINKED MATRIX

● Cross-linked polymers provide a strong layer of protection to actives from heat, moisture and air.

● Can enclose a variety of actives (proteins, vitamins, minerals, probiotics, amino acids, herbs, enzymes, etc.)

● Multiple actives can be incorporated into one dosage form.

● Protects nutrients during transit through the body.

● Allows targeting of specific release profiles.

CORE-SHELL

● Particle size of 250 to 1500 microns

● Provides stability of the active and taste improvement.

● Provides a barrier between two or more incompatible substances, protecting actives from humidity and moisture.

● Designed to control the release of the active ingredients.

© 2

01

9 C

UR

E P

harm

aceutical

CUREpodsTM


➽ Various controlled release possibilities, including fast, slow, temperature- and pH-triggered

➽ High-dose actives

➽ Chewable, shelf-stable, palatable flavor, in various shapes sizes and colors

➽ Can simultaneously load fat soluble and water soluble actives

➽ Can incorporate functional polysaccharides and proteins

➽ Overcomes problems with poorly soluble and poorly absorbed nutrients

KEY BENEFITS

© 2

01

9 C

UR

E P

harm

aceutical

CUREpodsTM

Key DifferentiatorsCUREPods™ Traditional gummies

Maximum % of active ingredient 60% - 90% 20-30%

Actives protected from moisture and air Yes No

Controlled speed of release Fast, slow No

pH-triggered release Yes No

Temperature-triggered release Yes No

Sugar needed to mask bitters None needed Varies

GMO base materials Non-GMO Varies

Shelf-stable Yes Varies

© 2

01

9 C

UR

E P

harm

aceutical

MORE ACTIVE INGREDIENT

High load of active ingredient on a single CUREfilm® (~200mg)

CUREpodTM can load up to 90% of total weight in active ingredient.

MULTIPLE ACTIVES

Multiple active ingredients can be co-formulated, including hydrophilic and lipophilic molecules within the same dosage form.

ADVANCED TASTE MASKING

CUREform™ products use advanced taste-masking technology and deliver a pleasant overall mouth feel.

CUREformTM

Competitive Differentiators

CONTROLLED DELIVERY

Various oral delivery methods and multiple kinetic profiles offer significant solubility and absorption benefits.

© 2

01

9 C

UR

E P

harm

aceutical

CUREformTM

Patient Benefits

QUICK DISSOLVENo liquid needed to administer

Optimized for palatability

FEWER SIDE EFFECTSPotential to reduce the dose

and avoid the GI tract

CUSTOMIZABLEMultiple active

ingredients in one dose

PORTABLELightweight and easy to

store and transport, and no water needed to take

NO PILLS TO SWALLOWIdeal for consumers that

cannot swallow pills

FAST SYMPTOM RELIEFRapid and/or sustained

delivery of active ingredients

© 2

01

9 C

UR

E P

harm

aceutical

A blended strategy of patents, trade secrets and proprietary equipment design.

Our IP Portfolio includes:

➽ Film compositions and methods of manufacturing

➽ Chewable compositions and methods of manufacturing

➽ Encapsulation compositions and methods

➽ Cannabinoid extraction and formulated extracts

Our IntellectualProperty

13ISSUED U.S. PATENTS

11PATENTSPENDING

© 2

01

9 C

UR

E P

harm

aceutical

● cGMP 25,000 sq ft production plant in Oxnard, CA

● FDA-registered and audited facility ● Clean room environment● Pharmaceuticals, dietary supplements

and controlled substances (DEA schedule 1 manufacturing license)

● Expansion capability● Custom drug delivery systems

developed in a design control process

Our Vertically Integrated Operations

PROCESSDEVELOPMENT

PACKAGE DESIGN & BRANDING

cGMP MANUFACTURING FACILITY

R&D / SCIENCE / FORMULATION FEASIBILITY

MARKET FEASIBILITY

© 2

01

9 C

UR

E P

harm

aceutical

GOAL:

Bioequivalent CUREfilm® P.O. formulation designed for a 505(b)(2) regulatory approval

STUDY DRUGS:

CUREfilm® Artelutrine (2 active combination drug) vs. COARTEM Dispersible Tablets

RESULT:

CUREfilm® formulation lead to equivalent Tmax, Cmax and AUC in rabbit model

Proof OfPlatform

© 2

01

9 C

UR

E P

harm

aceutical

GOAL:

Bioequivalent CUREfilm® P.O. formulation designed for a 505(b)(2) regulatory approval

STUDY DRUGS:

⅓ of 300mg Isoniazid 3-layer CUREfilm® vs. 100mg Nydrazid tablet

RESULT:

3-layer high dose CUREfilm® formulation lead to equivalent Tmax and Cmax in dog model

Proof OfPlatform

© 2

01

9 C

UR

E P

harm

aceutical

STUDY:

Human case studies evaluating 25-hydroxyvitamin D levels in patient serum under fasting conditions after weekly treatment over 12 weeks

STUDY DRUG:

1.25mg Cholecalciferol CUREfilm D (equivalent to 50K IU Vitamin D3)

RESULT:

CUREfilm D was effective at increasing 25-hydroxyvitamin D in patient blood

Patient Age Gender Pre treatment 25-hydroxyvitamin D levels

12-week Post treatment 25-hydroxyvitamin D levels

Delta

1 35 Male 32.9 ng/ml 58.7 ng/ml 25.8 ng/ml (+78%)

2 63 Male 28 ng/ml 95.8 ng/ml 67.8 ng/ml (+242%)

3 55 Male 35.4 ng/ml 50.9 ng/ml 15.5 ng/ml (+44%)

4 60 Female 31.5 ng/ml 78.9 ng/ml 47.4 ng/ml (+150%)

Proof OfPlatform

© 2

01

9 C

UR

E P

harm

aceutical

STUDY:

Ivermectin mouse study at the USC Department of Pharmacology using CUREdots™

RESULT:

With CUREdots, there is no trauma to the animal as compared to oral gavage and ensures equivalent alcohol intake between placebo and untreated groups leading to a more accurate efficacy study.

Animal Drug Delivery with CUREdots™

+++

Fig. 1 Alcohol intake by mice receiving no treatment (N/A) or placebo and drug through gavage

Fig. 2 Alcohol intake by mice receiving no treatment (N/A) or placebo and drug with CUREdots

© 2

01

9 C

UR

E P

harm

aceutical

NUTRACEUTICALS PHARMACEUTICALS CANNABINOIDS

1 2 3

• No FDA approval required • Faster and cheaper to launch

than drugs • Growing wellness market and

focus on the endocannabinoid system (ECS)

• Permits rapid optimization of production capabilities

• Drives innovative formulations with higher doses of active ingredients

• Greater impact for patients• 505(b)(2) regulatory pathway for

faster approvals while maintaining exclusivity

• Revenues from development fees, license fees, milestone payments, manufacturing fees and royalties.

• Potential development as nutraceutical and pharmaceutical

• Encapsulation to improve bioavailability of cannabinoids

and terpenes• DEA schedule 1 license to

manufacture cannabinoid products

• Global IP license with Canopy Growth

NUTRACEUTICALS

1

StrategicApproach

We employ a three-pronged approach to market penetration:

© 2

01

9 C

UR

E P

harm

aceutical

Formulation Development/

Preclinical

Manufacturing Scale Up

Launch

CUREfilm ® BCP

CUREfilm ® BLUE

CUREfilm ® D

Nutraceutical PharmaceuticalKEY

CUREform ® CANNA

Cannabinoids

ClinicalDevelopment

CUREfilm ® SLEEP

ProductPipeline

© 2

01

9 C

UR

E P

harm

aceutical

PRODUCT STATUS

PRODUCT DIFFERENTIATION

25mg and 50mg of Sildenafil

● Manufacturing scale up

● 505(b)(2) pathway in US

● Exclusive partnership for distribution in

ASEAN territories● US launch in 2021

● Faster onset● Ease of dosing● Discreet with no

water needed● Breath freshening

Market is expected to grow exponentially over the next 10 years.

Patent expiration and availability of the drug in various dosage forms will help grow the market.

$3.5B ● PIND meeting with FDA completed


● 505(b)(2) pathway

in US confirmed

● Potential for faster onset

● Ease of dosing● Discreet with no

water needed● Breath freshening

global market

6% CAGR over the next 5 years.

Sildenafil preferred ED drug (>55% all sales)

B2B, B2C and private clinics (~ 50% all sales) seek differentiated products for patients

$5B

Pharmaceuticals: CUREfilm® BLUE

#PoweredByCUREfilm

© 2

01

9 C

UR

E P

harm

aceutical

$50B market projected by 2029*

Multiple potential indications

Indication-specific partnership with Canopy Growth

PRODUCT STATUS


*Source: Statista Research Department 2019

Synthetic and plant derived cannabinoid CUREfilm®

● Preclinical development and testing under DEA license

$2B global market*

● Optimized pharmacokinetics

● Effective taste masking

● cGMP facility and processes

Pharmaceuticals: CUREfilm® Canna

#PoweredByCUREfilm

© 2

01

9 C

UR

E P

harm

aceutical

MARKET POTENTIAL

PRODUCT STATUS


Two different melatonin-

based daily dietary

supplements to promote

healthy sleep patterns

● ID LIFE SLEEPTM Launched 2017

● SLEEP STRIPZZZTM Launched 2018

● Potential for additional distributors and CUREpod application

$850MMelatonin supplement sales reached $851 million in 2016 and projected to top $1.5 billion by 2021*

● Convenient thin film dosage form

● Rapid onset● Patent pending

combination of ingredients that promote both sleep and recovery


*Source: Technavio 2017

Nutraceuticals: CUREfilm® Sleep

#PoweredByCUREfilm

© 2

01

9 C

UR

E P

harm

aceutical

50,000 IU of Vitamin D3

delivered with the

CUREfilm® platform as a

high potency supplement

PRODUCT STATUS


● Exclusive distribution partnership for the United States,

Middle East and Africa

$1.1BVitamin D supplementation is projected to reach

$1.7 billion over next 5 years*


● Weekly dose● Vitamin D3 - the

physician recommended form of Vitamin D

● Convenient thin film

dosage form● cGMP facility and

processes

*Source: MarketsandMarkets Analysis

Nutraceuticals: CUREfilm® D

#PoweredByCUREfilm

© 2

01

9 C

UR

E P

harm

aceutical

PRODUCT STATUS


*Source: Grand View Research **Persistence Market Research

Contains 30mg of β Caryophyllene, an inflammation-fighting and

analgesic terpene

● Formulation optimization

● Seeking distribution partners

● Potential for CUREpod

application

$261MAnti-inflammatory supplementation with turmeric (curcimin) in 2016*

● No solid dosage forms currently on the market


● Non GMO, Gluten

Free

$25BImmune health supplementation is projected to reach $25 billion by 2025**

Nutraceuticals: CUREfilm® BCP

#PoweredByCUREfilm

© 2

01

9 C

UR

E P

harm

aceutical

PRODUCT STATUS


*Source: WiseGuy Reports 2019

Low-dose hemp CUREfilm® and CUREpods™

● Development for Canopy Growth

● Partnership opportunities to develop hemp CBD CUREpod™ and CUREfilm® in select territories subject to applicable regulations

$150M global market

28% CAGR over the next 5 years

● Quick dissolve and release

● Increased absorption● Effective taste

masking● cGMP facility and

processes

Nutraceuticals: CUREform® Canna

#PoweredByCUREfilm #PoweredByCUREpods

© 2

01

9 C

UR

E P

harm

aceutical

Capitalization(as of 6/1/19)

Total Authorized Shares 150,000,000

Shares Issued and Outstanding 43,390,944

Fully Diluted Shares Outstanding 74,954,160

Public Float 12,430,243

Issued Options 4,014,756

Unissued Options (incentive plan) 985,244

Issued warrants 14,680,842

Convertible Debt Outstanding $550,000

© 2

01

9 C

UR

E P

harm

aceutical

● Formerly President and CEO of InnoZen Inc., CEO of Gel Tech LLC, CEO of Bio Delivery Technologies Inc.

● Lead the development of several drug delivery technologies and commercial brand extensions including Chloraseptic™, Suppress™, as well as Pediastrip™,

● B.S. degree in Biological Life Sciences; Masters Certificate in Applied Project Management , Master’s in Public Health, Masters in Wellness, Post Graduate Qualification at the University of Cambridge.

● Formerly Head of Innovation at Children’s Hospital Los Angeles, licensing officer at The Scripps Research Institute and held research, clinical and business development positions held at GlaxoSmithkline Biologicals.

● Founder and director of one of seven national FDA-funded pediatric medical device accelerators.

● Masters in Biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.

Jessica RoussetCOO

● Formerly CFO, vice president and general manager positions with several venture and private equity backed companies including Inogen, Medical Analysis Systems (acquired by Thermo Fisher Scientific), CDTi Advanced Materials, and Abrisa Technologies.

● Earlier experience includes management roles with Pepsi and in public accounting.

● CPA (inactive) with a B.S., Business Administration from California Polytechnic State University, San Luis Obispo.

MikeRedardCFO

Our Team: Officers

Robert DavidsonCEO

© 2

01

9 C

UR

E P

harm

aceutical

● Over 35 years of experience leading technical teams.

● Leadership roles in process development at Amgen Thousand Oaks and Ireland

● Management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals.

● Trained as microbiologist and chemist at Brigham Young University.

● Formerly Project Leader with the Boston Consulting Group focused on corporate and network strategy, operations, marketing and post-merger integration initiatives.

● PhD in Immunology from the University of Pennsylvania; BSc. in Bio-Medical sciences from Tel-Aviv University in Israel.

Vered GigiVP, Strategy & Business Development

● Formerly Chief Accounting Officer and Controller at InnoZen, Inc.

● Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. CPA and B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

Mark UdellCAO

Our Team: Senior Leadership

Steven RuhlVP, Manufacturing

© 2

01

9 C

UR

E P

harm

aceutical

● Registered U.S. patent attorney and partner at Carlson Caspers. Over 25 years experience in pharmaceutical patent law.

● JD - Temple University School of Law, MBA - University of Massachusetts, Amherst, M.Sc. Chemistry - Villanova University, B.Sc. Chemistry - Fordham University.

● Admitted to the Supreme Courts of MN, NJ, ND and PA, the U.S. District Court for the District of NJ, U.S. Court of Appeals for the Federal Circuit and the U.S. Patent and Trademark Office.

● President and CEO of PTS Consulting, LLC and has over 30 years of experience in the pharmaceutical and related industries.

● Formerly held leadership positions at Midland Pharmaceutical, ratiopharm GmbH (now Teva), Martec Scientific (now Nostrum Lab) and Martec Pharmaceutical

● B.S. and M.S. in Pharmacy from the University Department of Chemical Technology, India, an M.B.A. from Andrews University, Michigan and Kansas State University, Kansas

Paul SudhakarRegulatory Counsel

Our Team: Key Advisors

Gary SpeierIP Counsel

© 2

01

9 C

UR

E P

harm

aceutical

Board of DirectorsWilliam Yuan (Chairman of the Board)

● Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm.

● 23 years in global finance experience.● Key strategist and advisor to international institutions. U.S.

companies include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News.

● Guided leading Asian institutions like Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp.Led Merrill Lynch Asset Management Asia,

● Managed one of the largest pension / retirement funds in the world, with a $488 billion portfolio.

● Member of the International Who’s Who of Finance, Technology, Media and Telecom.

● B.S. in Economics from Cornell University● Attended as a Mason Fellow at Harvard University’s John F.

Kennedy School.

Lauren Chung, Ph.D.

● 20 years of healthcare investment management and advisory experience.● Founded MINLEIGH LLC. identifying, evaluating and partnering with

companies for investments and various strategic, operational, and commercial planning, as well as providing growth capital.

● Managing Director in Healthcare Research at WestPark Capital.● Former Senior Healthcare Equity Analyst at Maxim Group. ● Co Founder of Tokum Capital , a global healthcare fund.● Managed healthcare investment portfolios at RBR Capital, Kingdon

Capital, and Pequot Capital. ● Recognized research scientist conducting cutting edge research in the field

of Alzheimer’s disease and Angelman Syndrome at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.

● Serves as a board member in various private healthcare companies. ● PhD in Neuropathology from Columbia University-College of Physicians &

Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.

© 2

01

9 C

UR

E P

harm

aceutical

Rob Davidson

● CEO of CURE Pharmaceutical ● Former President and CEO of InnoZen Inc., CEO of Gel Tech LLC,

CEO of Biodelivery Technologies Inc., and Director of HealthSport Inc.

● ODF expert responsible for the development of several drug delivery technologies and commercial brand extensions.

● Has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film.

● B.S., Biological Life Sciences, University of the State of New York, Excelsior College.

● Master’s Certificate, Applied Project Management , Villanova University

● Master’s, Public Health from American Military University, Virginia

● Masters in Health and Wellness from Liberty University, Virginia ● Certified Performance Enhancement Specialist and Fitness

Nutrition Specialist, National Academy of Sports Medicine● Post-Graduate Qualification, University of Cambridge.

Anya Goldin

● 28 years of experience in law, private equity, venture capital, healthcare and telecommunications industries.

● Former international business consultant ● A practicing attorney at Nolan Heimann law firm ● Co-founded Provenance Laboratories, a technology start-up. ● 17 years in leadership as a managing partner at Latham & Watkins ● Served as the General Counsel, Vice President and Chair of the Risk

Management Committee of a $20-billion London Stock Exchange-listed conglomerate and served on the boards of eight public and private companies in Europe, Russia, India and the UK

● Vice Chair of the Board of Directors for a global private equity fund ● On the Advisory Board of a California private equity fund, Lumia Capital.● On the Board of Trustees of Westmark School, and on the Board of the LA

Chapter of Berkeley Law Alumni ● A member of the State Bar of California● BA in Mass Communications from University of California Berkeley● JD from University of California Berkeley School of Law

Board of Directors(continued)

© 2

01

9 C

UR

E P

harm

aceutical

Board of Directors(continued)

Joshua Held

● Currently the President of Form Factory Inc. a wholly owned subsidiary of Acreage Holdings (ARCG.CN) the largest multi-State cannabis operator licensed in 20 States.

● Founder and CEO of Chemistry Holdings, Inc. a formulation technology company that creates innovative, sustainable delivery systems for a variety of industries. Chemistry Holdings was recently acquired by Cure Pharmaceutical.

● CEO and founder of Made by Science (rebranded as Form Factory Inc) . a private company acquired by Acreage Holdings for $160 Million in December of 2018.

● Former Vice President of Investments for JP Morgan, managing more than $100 million in investment dollars for high-net-worth individuals and families.

● Bachelor of Arts from the California State University, Long Beach.

Ruben Jose King-Shaw Jr.

● C-suite positions with leading private companies including Steward Health Care System, LLC, Neighborhood Health Partnership, Inc. and JMH Health Plan.

● Former Board member, Cotiviti Holdings, Inc. and current Board member, Intelligent Retinal Imaging Systems of Pensacola, FL.

● Former Lead Director of the Board at Athenahealth; Independent Living Systems, of Miami, FL; and WellCare Health Plans, Inc. of Tampa, FL.

● Served on the Obama Administration's Medicare Program Advisory and Oversight Committee,

● COO and deputy administrator of the Centers for Medicare and Medicaid Services, George W. Bush administration.

● Advisor, healthcare policy to the Trump Administration.● Senior advisor to the Secretary of the U.S. Treasury, health care tax

policies. ● B.S., Industrial and Labor Relations, Cornell University, Master of

Health Service Administration and a Master of International Business, Florida International University. Advanced studies in Corporate Governance at the Harvard Business School.

© 2

01

9 C

UR

E P

harm

aceutical

Board of Directors (continued)

Gene Salkind, MD

● Board certified in neurological surgery by the American Board of Neurological Surgery and completed various residencies, fellowships and postgraduate training at Abington Memorial hospital, The Graduate Hospital, Veteran’s Administration Hospital, Pennsylvania Hospital, Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania.

● MD from Temple University School of Medicine and his Bachelor of Arts from the University of Pennsylvania.

● Numerous faculty, hospital and administrative appointments at virtually every major hospital in the northeastern Philadelphia and surrounding areas.

● Prolific pharmaceutical investor including Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, acquired by Johnson & Johnson for $4.9 billion in stock.

● Sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics.

© 2

01

9 C

UR

E P

harm

aceutical

Advisors

Michael Willner, Esq.

● Founder of Willner Properties Services, Inc., a PA based real estate development, leasing and management company specializing in both commercial and residential properties.

● Founder of Willner Capital, Inc., a FL based investment concern that has played an activist role with several publicly traded companies.

● Investor in biotech, technology and security companies, with recent focus in cannabis related pharmaceutical companies

● Served on the Board of Directors of publicly traded Meridian Bank, served as Vice Chairman of the Board of Directors of Intervoice, Inc.

● Held positions at Milbank, Tweed, Hadley & McCloy and Arthur Andersen & Company

● Juris Doctor degree from Emory University Law School and CPA

Michael Neely, MD

● Director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years.

● Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles.

● Research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients.

● Member of the United States Food and Drug Administration Anti- infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology.

© 2

01

9 C

UR

E P

harm

aceutical

Advisors (continued)

Teresa Virgallito

● Expert in physical and mechanical encapsulation, ingredient engineering, food law regulations and food safety, microbiology and chemical instrumentation.

● Previously EVP of Chemistry Holdings, Inc. ● She has developed drug delivery and formulation solutions

for Procter & Gamble, Kraft, Unilever, Cargill, the U.S. Army, and the U.S. Navy.

● Through her research and commercialization endeavors, she has gained a wealth of knowledge and expertise in regard to the following encapsulation methods: Co-acervation, In-situ Polymerization, Interfacial Polymerization, Fluid Bed Technology, Spray Chilling, Hot Melt Systems, Prilling, Pan Coating, Phase Separation, and Spray Drying.

● Member of the Controlled Release Society active on several CRS committees.

© 2

01

9 C

UR

E P

harm

aceutical

CompanyDisclaimer

This Investor Presentation is supplied for informational purposes only and does

not constitute (1) an offer to sell, or the solicitation of an offer to buy, any securities of CURE Pharmaceutical, or (2) a promise or representation that any

such offer will be made to the recipient or any other party.

The offering is being made only to qualified investors. The offering shall be made

pursuant to documents reasonably acceptable to the Company and the Investors, which agreements shall contain, among other things, (i) short form, basic representations and warranties by the Company, and (ii) covenants of the Company reflecting the provisions set forth herein and appropriate conditions of closing.

Documents to be drafted by counsel to the company. Read those documents

before making an investment decision. The securities are being offered in reliance upon exemptions from registration under the Securities Act of 1993 and only in the states in which the offering of securities is registered or is exempt from registration and by broker-dealers authorized to do so.